CO2020015383A2 - Anticuerpos dirigidos contra il-11 - Google Patents

Anticuerpos dirigidos contra il-11

Info

Publication number
CO2020015383A2
CO2020015383A2 CONC2020/0015383A CO2020015383A CO2020015383A2 CO 2020015383 A2 CO2020015383 A2 CO 2020015383A2 CO 2020015383 A CO2020015383 A CO 2020015383A CO 2020015383 A2 CO2020015383 A2 CO 2020015383A2
Authority
CO
Colombia
Prior art keywords
directed against
antibodies directed
binding
prophylaxis
antigen
Prior art date
Application number
CONC2020/0015383A
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Original Assignee
Boehringer Ingelheim Int
Nat Univ Singapore
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Nat Univ Singapore, Singapore Health Serv Pte Ltd filed Critical Boehringer Ingelheim Int
Publication of CO2020015383A2 publication Critical patent/CO2020015383A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Se proporcionan moléculas de unión a antígeno capaces de unirse a IL-11 y métodos de tratamiento médico y profilaxis usando las mismas.
CONC2020/0015383A 2018-06-13 2020-12-09 Anticuerpos dirigidos contra il-11 CO2020015383A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1809699.0A GB201809699D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies
PCT/EP2019/065598 WO2019238882A1 (en) 2018-06-13 2019-06-13 Il-11 antibodies

Publications (1)

Publication Number Publication Date
CO2020015383A2 true CO2020015383A2 (es) 2021-04-19

Family

ID=63042160

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0015383A CO2020015383A2 (es) 2018-06-13 2020-12-09 Anticuerpos dirigidos contra il-11

Country Status (24)

Country Link
US (2) US11084874B2 (es)
EP (1) EP3807314A1 (es)
JP (1) JP2021535733A (es)
KR (1) KR20210031690A (es)
CN (1) CN113056481A (es)
AU (1) AU2019286795A1 (es)
BR (1) BR112020025443A2 (es)
CA (1) CA3102483A1 (es)
CL (1) CL2020003223A1 (es)
CO (1) CO2020015383A2 (es)
CR (1) CR20210009A (es)
DO (1) DOP2020000245A (es)
EA (1) EA202092668A1 (es)
EC (1) ECSP21000695A (es)
GB (1) GB201809699D0 (es)
IL (1) IL279356A (es)
JO (1) JOP20200309A1 (es)
MA (1) MA52884A (es)
MX (1) MX2020013583A (es)
PE (1) PE20211498A1 (es)
PH (1) PH12020552232A1 (es)
SG (1) SG11202011782XA (es)
TW (1) TW202003560A (es)
WO (1) WO2019238882A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
MX2019007020A (es) 2016-12-16 2019-10-21 Singapore Health Serv Pte Ltd Anticuerpos il-11.
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
CA3126322A1 (en) * 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
CA3146344A1 (en) 2019-05-03 2020-11-12 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
US20230235029A1 (en) * 2020-07-20 2023-07-27 Integrated Biotherapeutics, Inc. Broadly neutralizing binding molecules against marburgviruses
WO2022033538A1 (zh) * 2020-08-13 2022-02-17 广东东阳光药业有限公司 Il-11的抗体及其应用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
KR20230150287A (ko) 2021-02-26 2023-10-30 바이엘 악티엔게젤샤프트 비정상적 자궁 출혈의 치료에 사용하기 위한 il-11 또는 il-11ra의 억제제
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
CN115975027B (zh) * 2021-08-12 2023-10-20 广东东阳光药业股份有限公司 Il-11人源化抗体及其应用
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
CN116891528A (zh) * 2022-01-29 2023-10-17 迈威(上海)生物科技股份有限公司 一种抗白介素-11的抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) * 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
MX2019007020A (es) * 2016-12-16 2019-10-21 Singapore Health Serv Pte Ltd Anticuerpos il-11.
RU2016151730A (ru) * 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11

Also Published As

Publication number Publication date
GB201809699D0 (en) 2018-08-01
SG11202011782XA (en) 2020-12-30
CN113056481A (zh) 2021-06-29
AU2019286795A1 (en) 2021-01-28
US11084874B2 (en) 2021-08-10
CR20210009A (es) 2021-06-21
TW202003560A (zh) 2020-01-16
ECSP21000695A (es) 2021-03-31
US20210230266A1 (en) 2021-07-29
EA202092668A1 (ru) 2021-05-18
WO2019238882A1 (en) 2019-12-19
JP2021535733A (ja) 2021-12-23
IL279356A (en) 2021-01-31
CA3102483A1 (en) 2019-12-19
KR20210031690A (ko) 2021-03-22
CL2020003223A1 (es) 2021-07-30
BR112020025443A2 (pt) 2021-03-16
MX2020013583A (es) 2021-04-13
MA52884A (fr) 2021-04-21
PE20211498A1 (es) 2021-08-11
DOP2020000245A (es) 2021-10-31
EP3807314A1 (en) 2021-04-21
PH12020552232A1 (en) 2021-06-28
JOP20200309A1 (ar) 2020-11-30
US20200031918A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
ECSP21000695A (es) Anticuerpos dirigidos contra il-11
CL2020003218A1 (es) Anticuerpos dirigidos contra il-11ra
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
CL2019002542A1 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
PE20201419A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
EA201890572A1 (ru) Биофармацевтические композиции
BR112020015498A8 (pt) Anticorpos anti-pd-1
CO2019004561A2 (es) Métodos de tratamiento de una lesión renal aguda
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
DK3630177T3 (da) Behandlingsparadigme til et anti-cd19-antistof og venetoclax-kombinationsbehandling
EA201891351A1 (ru) Вспениваемая композиция галобетазола и способ её применения
EA202191779A1 (ru) Способ получения антраниламидов
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций